Opko Health

OPKO Health, Inc. is a multi-national pharmaceutical and diagnostics company that aims to establish industry-leading positions in large and rapidly growing medical markets by leveraging our discovery, development, and commercialization expertise and our novel and proprietary technologies. We intend to leverage our global commercialization expertise to pursue acquisitions of commercial businesses that will both drive our growth and provide geographically diverse sales and distribution opportunities. We have and may continue to make investments in other early stage companies that we perceive to have valuable proprietary technology and significant potential to create value for OPKO as a shareholder. Our Focus is on Point-of-Care and Novel Molecular Diagnostics, Proprietary Pharmaceuticals, and Vaccines. Since 2009, OPKO has completed five national and international acquisitions contributing to its technology and commercial operations. OPKO continues to explore acquisition opportunities for complementary pharmaceuticals, compounds, technologies, and businesses. We expect our future growth to arise from leveraging our proprietary technology, development strengths, and pursuit of complementary and strategic acquisitions and investments.
Company Growth (employees)
Type
Public
HQ
Miami, US
Founded
2007
Size (employees)
6,041 (est)
Website
opko.com
Opko Health was founded in 2007 and is headquartered in Miami, US

Key People at Opko Health

Phillip Frost

Phillip Frost

CEO
Jane H. Hsiao

Jane H. Hsiao

CTO

Opko Health Office Locations

Opko Health has offices in Miami and Woburn
Miami, US (HQ)
4400 Biscayne Blvd

Opko Health Data and Metrics

Opko Health Financial Metrics

Opko Health's revenue was reported to be $296.1 m in Q1, 2017
USD

Revenue (Q1, 2017)

296.1 m

Net income (Q1, 2017)

(31 m)

EBIT (Q1, 2017)

(41.7 m)

Market capitalization (15-Aug-2017)

3.4 b

Cash (31-Mar-2017)

131.1 m
Opko Health's current market capitalization is $3.4 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

96.5 m91.1 m491.7 m1.2 b

Revenue growth, %

(6%)440%148%

Gross profit

47.7 m43.1 m449.8 m

Gross profit Margin, %

49%47%91%

R&D expense

111.2 m

General and administrative expense

490.9 m

Operating expense total

176.2 m236.9 m590.2 m1.3 b

EBIT

(79.6 m)(145.8 m)(98.5 m)(73.3 m)

EBIT margin, %

(82%)(160%)(20%)(6%)

Interest expense

13.8 m12.3 m8.4 m7.4 m

Interest income

376 k771 k255 k478 k

Income tax expense

(1.7 m)(24 k)113.7 m56.1 m

Net Income

(117.3 m)(174.6 m)(31.4 m)(25.1 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

23.5 m19.8 m30.1 m42.4 m143 m291 m357.1 m298 m296.1 m

R&D expense

16.2 m20.5 m25.5 m29.6 m18.9 m27.8 m31.3 m24.4 m26 m

General and administrative expense

14.9 m14 m17.4 m20.9 m55.2 m128 m117.5 m124.8 m136.7 m

Operating expense total

31.1 m34.5 m42.9 m50.5 m74.2 m155.8 m148.9 m149.3 m162.7 m

EBIT

(34.9 m)(48.2 m)(56.9 m)(25.4 m)(8.2 m)(27.5 m)28.3 m(23.6 m)(41.7 m)

EBIT margin, %

(148%)(244%)(189%)(60%)(6%)(9%)8%(8%)(14%)

Interest expense

(4.7 m)(2.4 m)(2.6 m)(986 k)(2.7 m)(1.8 m)(2.2 m)(2 m)(1.4 m)

Interest income

7 k402 k8 k5 k13 k43 k135 k163 k249 k

Income tax expense

(101 k)(294 k)(5.5 m)(251 k)93 m20.5 m(15.9 m)20 m6.9 m

Net Income

(26.1 m)(50 m)(118 m)(43.2 m)128.2 m(12 m)15.5 m(15 m)(31 m)
USDFY, 2013FY, 2015FY, 2016

Cash

185.8 m193.6 m168.7 m

Accounts Receivable

19.8 m193.9 m220.3 m

Inventories

19.1 m26.9 m47.2 m

Current Assets

242.7 m454.1 m483.6 m

PP&E

131.8 m122.8 m

Goodwill

226.4 m743.3 m704.6 m

Total Assets

1.4 b2.8 b2.8 b

Accounts Payable

13.4 m72.5 m53.4 m

Current Liabilities

91.9 m251.9 m263.3 m

Non-Current Liabilities

426.7 m567.9 m411.5 m

Total Liabilities

518.5 m819.8 m674.8 m

Additional Paid-in Capital

1.4 b2.7 b2.8 b

Retained Earnings

(503.2 m)(704.9 m)(730 m)

Total Equity

873 m2 b2.1 b

Financial Leverage

1.6 x1.4 x1.3 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

134 m118.3 m348.2 m221.2 m212.1 m175 m156 m144.6 m131.1 m

Accounts Receivable

23.1 m21.2 m19.1 m27 m189.7 m204.5 m213.4 m223.8 m238.9 m

Inventories

18.3 m16.7 m18.3 m20.5 m40.7 m40.6 m42 m43.2 m47.5 m

Current Assets

183 m163.1 m394 m278.3 m517.4 m453.5 m505.6 m502.1 m459.9 m

PP&E

126.8 m133.9 m128.3 m125.5 m126.3 m

Goodwill

226 m224.8 m223.2 m289.6 m761.2 m747 m691.1 m700.5 m706 m

Total Assets

1.3 b1.3 b1.5 b1.5 b3 b2.8 b2.8 b2.8 b2.8 b

Accounts Payable

10 m8.8 m10.5 m16 m78 m73.4 m61.1 m58.5 m74.6 m

Current Liabilities

79.4 m76.8 m182.8 m180.5 m357.6 m267.2 m281.2 m254.5 m265 m

Non-Current Liabilities

334.9 m331.1 m516.8 m518 m688.9 m528.1 m477.1 m440.1 m388.1 m

Additional Paid-in Capital

1.5 b1.5 b1.6 b1.7 b2.7 b2.7 b2.7 b2.8 b2.9 b

Retained Earnings

(573.2 m)(621.9 m)(792 m)(834.7 m)(706.5 m)(716.8 m)(701.3 m)(716.3 m)(728.4 m)

Total Equity

827 m2 b2 b2 b2.1 b2.1 b

Financial Leverage

1.8 x1.5 x1.4 x1.4 x1.3 x1.3 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(117.3 m)(174.6 m)(31.4 m)(25.1 m)

Depreciation and Amortization

11.1 m14.9 m28 m64.4 m

Accounts Receivable

19.8 m(3.9 m)(29 m)(25.6 m)

Inventories

19.1 m3.2 m(4.4 m)

Accounts Payable

13.4 m(3.9 m)(18.1 m)(19.8 m)

Cash From Operating Activities

158.4 m(90.4 m)164 m32 m

Capital Expenditures

(4.7 m)(10.8 m)(18.5 m)

Cash From Investing Activities

(5.7 m)(99.2 m)(20.7 m)

Cash From Financing Activities

7.3 m33 m(35.2 m)

Interest Paid

6.3 m4.6 m2.9 m

Free Cash Flow

(85.6 m)174.9 m13.5 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(26.1 m)(50 m)(118 m)(43.2 m)128.2 m(12 m)15.5 m(15 m)(31 m)

Depreciation and Amortization

2.8 m2.7 m2.7 m3.2 m8.1 m13.4 m15.8 m18.1 m17.9 m

Accounts Receivable

23.1 m21.2 m19.1 m27 m189.7 m204.5 m213.4 m223.8 m238.9 m

Inventories

40.6 m

Accounts Payable

10 m8.8 m10.5 m16 m78 m73.4 m61.1 m58.5 m74.6 m
USDY, 2017

Revenue/Employee

49 k

Financial Leverage

1.3 x

Opko Health Market Value History

Traffic Overview of Opko Health

Opko Health Online and Social Media Presence

Opko Health News and Updates

BRIEF-Frost Gamma Investments says buys 10,000 shares of Opko Health Inc's common stock

* Frost Gamma Investments says buys 10,000 shares of Opko Health Inc's common stock on July 11- SEC filing Source text for Eikon: Further company coverage:

Futures higher as markets await Yellen comments

(Reuters) - U.S. stock index futures were higher on Tuesday ahead of Federal Reserve Chair Janet Yellen's comments on the economy and Britain's vote on its European Union membership on Thursday.

Opko Health Company Life and Culture

You may also be interested in